Explore /
Poster
/ Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK<em> </em>resistance mutations on amplicon-based liquid biopsy in ALK<em> </em>positive non-small cell lung cancer (NSCLC) patients (pts).

Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK resistance mutations on amplicon-based liquid biopsy in ALK positive non-small cell lung cancer (NSCLC) patients (pts).

Authors

Laura Mezquita

Medical Oncology Department, Gustave Roussy, Villejuif, France

Laura Mezquita , Aurélie Swalduz , Cecile Jovelet , Sandra Ortiz-Cuaran , David Planchard , Gonzalo Recondo , Jose Carlos Benitez , Karen Howarth , Clive D. Morris , Emma Green , Ludovic Lacroix , Luc Odier , Etienne Rouleau , Pierre Fournel , Caroline Caramella , Claire Tissot , Maurice Perol , Luc Friboulet , Benjamin Besse , Pierre Saintigny

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics and Tumor Biology (Nonimmuno)

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Circulating Biomarkers

Citation

J Clin Oncol 37, 2019 (suppl; abstr 3055)

DOI

10.1200/JCO.2019.37.15_suppl.3055

Abstract #

3055

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2018 ASCO Annual Meeting

An amplicon-based liquid biopsy for detecting <em>ALK</em> and <em>ROS1</em> fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.

An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.

First Author: Laura Mezquita

Poster

2020 ASCO Virtual Scientific Program

Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.

First Author: D. Ross Camidge

Poster

2023 ASCO Annual Meeting

Impact of <em>EML4-ALK</em> fusion variant and co-occurring <em>TP53</em> mutation on treatment duration of first-line next-generation ALK TKIs in <em>ALK </em>fusion+ NSCLC.

Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.

First Author: Kaushal Parikh

Poster

2022 ASCO Annual Meeting

Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with <em>ALK</em>-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.

Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.

First Author: Alessandra Bearz

FEATURED

Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK resistance mutations on amplicon-based liquid biopsy in ALK positive non-small cell lung cancer (NSCLC) patients (pts).

Authors

Laura Mezquita

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.

Poster

Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.

Poster

Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.

Poster

Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.